A Single Center, Open, Randomized, Placebo-controlled Study Investigating the Safety of Administration of Ilomedin in Addition to Standard Treatment in Patients Having Undergone Primary Percutaneous Coronary Intervention (PCI).

Trial Profile

A Single Center, Open, Randomized, Placebo-controlled Study Investigating the Safety of Administration of Ilomedin in Addition to Standard Treatment in Patients Having Undergone Primary Percutaneous Coronary Intervention (PCI).

Completed
Phase of Trial: Phase I/II

Latest Information Update: 16 Feb 2013

At a glance

  • Drugs Iloprost (Primary)
  • Indications Coronary artery disease; Embolism and thrombosis
  • Focus Adverse reactions
  • Sponsors Thrombologic
  • Most Recent Events

    • 01 Jun 2011 Status changed from recruiting to completed added as reported by ClinicalTrials.gov.
    • 01 Jun 2011 Actual end date (Jun 2011) added as reported by ClinicalTrials.gov.
    • 08 Oct 2010 Actual initiation date (Sep 2010) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top